# Prasinezumab

Source: https://onco.cc/drugs/da-prasinezumab/  
OnCo record `da-prasinezumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Prasinezumab is an investigational synuclein antibody studied mainly in Parkinson’s disease. It is not an approved dementia medicine.

## Summary

Listed as a same-target neighbour for Lewy-body biology. Parkinson’s trial results do not equal a dementia indication. Trial-only access.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Modality: mAb
- Mechanism: Investigational antibody against aggregated alpha-synuclein (primarily Parkinson’s programmes).

## Sources

- ClinicalTrials.gov NCT03100149: https://clinicaltrials.gov/study/NCT03100149

## Connected records

- diagnoses: [Dementia with Lewy bodies](https://onco.cc/diagnoses/dementia-with-lewy-bodies/), [Parkinson’s disease dementia](https://onco.cc/diagnoses/parkinsons-disease-dementia/)
- targets: [Alpha-synuclein](https://onco.cc/targets/da-target-alpha-synuclein/)
- companies: [Roche](https://onco.cc/companies/da-roche/)
- trials: [Prasinezumab (PASADENA / related)](https://onco.cc/trials/da-trial-prasinezumab/)

---
JSON: https://onco.cc/api/v1/entities/da-prasinezumab.json